Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05320692 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

StatusActive, Not Recruiting
PhasePhase 3
Started2022-08-09
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 11, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-12-10
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 425→confirmed 423
Study sitesdetails revised at 1 of 1 site
2025-02-15
Study Status, Study Design, Contacts/Locations v2
Primary completion date2024-07-30→2026-07-30
Enrollment target360→425
2022-10-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-04-25→confirmed 2022-08-09
Study sites0→1
2022-04-02
Original filing
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
Trial Details
NCT Number NCT05320692
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 423 participants
Start Date 2022-08-09
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-11